Skip to main content

1042-SE-3003 A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus

NCT04391569

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus

Associated Conditions

Epilepsy

Principal Investigator

Sponsor

Marinus Pharmaceuticals

The purpose of this research is to find out if ganaxolone can stop or decrease the seizure activity in participants who have SE and if ganaxolone is safe compared to placebo when given to participants who are on other anti-seizure medications. A placebo looks like the study drug but does not contain any active medicine. Researchers use a placebo to see if a study drug works better or is safer than not taking the study drug at all

This study is currently enrolling.